At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 88 enrolled
Drug / intervention
Vorolanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
In Brief
A Phase 2 clinical trial evaluating Vorolanib and Nivolumab for Thymic Carcinoma and 3 related conditions. Completed, enrolled 88 participants across 7 sites.
Detailed Summary
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who have progressed on platinum-based chemotherapy, and thymic carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Xcovery Holdings, Inc.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedJul 2018
Primary CompletionFeb 2024
Study CompletionApr 2024
TodayJul 2026
First PostedJul 11, 2018
Enrollment StartJul 10, 2018
Primary CompletionFeb 21, 2024
Study CompletionApr 27, 2024
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 8.0 years ago
Interventions
Vorolanibdrug
Given by mouth
Nivolumabbiological
Given by IV